Isotopic biomarker discovery and application in translational medicine

Drug Discovery Today

Volumn 15, Issue 3-4, 2010, Pages 127-136

  Bayele, Henry K ^a   Chiti, Arturo ^b   Colina, Rodney ^c   Fernandes, Octavio ^d   Khan, Baldip ^e   Krishnamoorthy, Rajagopal ^f   Özdaǧ, Hilal ^g   Padua, Rose Ann ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g ANKARA UNIVERSITY   (Turkey)

^h INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINIUM 225; ADENOVIRUS VECTOR; AMINO ACID; BIOLOGICAL MARKER; BISMUTH 212; BISMUTH 213; CHEMOKINE; COPPER 67; CYTOKINE; DOPAMINE 2 RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GALLIUM 67; IBRITUMOMAB TIUXETAN; INTERFERON REGULATORY FACTOR 7; IODINE 125; IODINE 131; LEAD 212; MESSENGER RNA; MICRORNA; PROTEOME; RADIOISOTOPE; RHENIUM 186; RHENIUM 188; SAMARIUM 153; SODIUM IODIDE I 131; THYMIDINE KINASE; TOSITUMOMAB I 131; TUMOR ANTIGEN; UNINDEXED DRUG; VASCULOTROPIN;

ANALYTIC METHOD; BONE METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG DESIGN; DRUG MONITORING; DRUG RESEARCH; FUNCTIONAL GENOMICS; FUNCTIONAL PROTEOMICS; GENE EXPRESSION PROFILING; HUMAN; IMMUNOTHERAPY; INFECTION; INFLAMMATORY DISEASE; LEUKEMIA; LIVER CELL CARCINOMA; MACROPHAGE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METABOLOMICS; MOLECULAR BIOLOGY; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN MODIFICATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

BIOLOGICAL MARKERS; COMMUNICABLE DISEASES; DIAGNOSTIC TECHNIQUES, RADIOISOTOPE; DRUG DISCOVERY; GENOMICS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; MOLECULAR IMAGING; PROTEOMICS; RADIOISOTOPES; TRANSLATIONAL RESEARCH;

EID: 75449083555     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.12.005     Document Type: Review

References (95)

1. Rifai N., et al. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24 (2006) 971-983
2. Lang L. High clinical trials attrition rate is boosting drug development costs. Gastroenterology 127 (2004) 1026
3. The International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431 (2004) 931-945
4. Hollstein M., et al. p53 mutations in human cancers. Science 253 (1991) 49-53
5. Doolittle B.R., et al. Detection of the mutated K-Ras biomarker in colorectal carcinoma. Exp. Mol. Pathol. 70 (2001) 289-301
6. Maheswaran S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359 (2008) 366-377
7. Schena M., et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 (1995) 467-470
8. Kalnina Z., et al. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 42 (2005) 342-357
9. Chen Y.R., et al. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J. Proteome Res. 5 (2006) 2727-2742
10. Kirmiz C., et al. A serum glycomics approach to breast cancer biomarkers. Mol. Cell. Proteomics 6 (2007) 43-55
11. Kyselova Z., et al. Alterations in the serum glycome due to metastatic prostate cancer. J. Proteome Res. 6 (2007) 1822-1832
12. Barrabés S., et al. Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer. Glycobiology 17 (2007) 388-400
13. Ueda K., et al. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer. J. Proteome Res. 6 (2007) 3475-3483
14. Veenstra T.D. Global and targeted quantitative proteomics for biomarker discovery. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 847 (2007) 3-11
15. Anderson N.L., and Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1 (2002) 845-867
16. Chaerkady R., and Pandey A. Applications of proteomics to lab diagnosis. Annu. Rev. Pathol. 3 (2008) 485-498
17. Ong S.E., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1 (2002) 376-386
18. Krüger M., et al. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 134 (2008) 353-364
19. Wu C.C., et al. Metabolic labeling of mammalian organisms with stable isotopes for quantitative proteomic analysis. Anal. Chem. 76 (2004) 4951-4959
20. Brun V., et al. Isotope-labeled protein standards: toward absolute quantitative proteomics. Mol. Cell. Proteomics 6 (2007) 2139-2149
21. Tannu N.S., and Hemby S.E. Two-dimensional fluorescence difference gel electrophoresis for comparative proteomics profiling. Nat. Protocols 1 (2006) 1732-1742
22. Monribot-Espagne C., and Boucherie H. Differential gel exposure, a new methodology for the two-dimensional comparison of protein samples. Proteomics 2 (2002) 229-240
23. Poznanović S., et al. Differential radioactive proteomic analysis of microdissected renal cell carcinoma tissue by 54 cm isoelectric focusing in serial immobilized pH gradient gels. J. Proteome Res. 4 (2005) 2117-2125
24. Seferovic M.D., et al. Quantitative 2-D gel electrophoresis-based expression proteomics of albumin and IgG immunodepleted plasma. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 865 (2008) 147-152
25. Nanavati D., et al. Stoichiometry and absolute quantification of proteins with mass spectrometry using fluorescent and isotope-labeled concatenated peptide standards. Mol. Cell. Proteomics 7 (2008) 442-447
26. Gygi S.P., et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17 (1999) 994-999
27. Tao W.A., and Aebersold R. Advances in quantitative proteomics via stable isotope tagging and mass spectrometry. Curr. Opin. Biotechnol. 14 (2003) 110-118
28. Schneider L.V., and Hall M.P. Stable isotope methods for high-precision proteomics. Drug Discov. Today 10 (2005) 353-363
29. Keshishian H., et al. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 6 (2007) 2212-2229
30. Ross P.L., et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3 (2004) 1154-1169
31. Gerber S.A., et al. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6940-6945
32. 18O into peptide fragments and its application for protein sequencing by electrospray and matrix-assisted laser desorption/ionization mass spectrometry. Electrophoresis 17 (1996) 945-953
33. Hood B.L., et al. Proteomic analysis of formalin-fixed prostate cancer tissue. Mol. Cell. Proteomics 4 (2005) 1741-1753
34. Stockwin L.H., et al. Proteomic analysis of plasma membrane from hypoxia-adapted malignant melanoma. J. Proteome Res. 5 (2006) 2996-3007
35. Hall M.P., and Schneider L.V. Isotope-differentiated binding energy shift tags (IDBEST) for improved targeted biomarker discovery and validation. Expert Rev. Proteomics 1 (2004) 421-431
36. O'Hara R.M., et al. Cell-surface and cytokine biomarkers in autoimmune and inflammatory disease. Drug Discov. Today 11 (2006) 342-347
37. 13C-labeled peptide standards. Proteomics 4 (2004) 1175-1186
38. Henley S.M., et al. Biomarkers for neurodegenerative diseases. Curr. Opin. Neurol. 18 (2005) 698-705
39. Cassell G.H. Infectious causes of chronic inflammatory diseases and cancer. Emerg. Infect. Dis. 4 (1998) 475-487
40. Censini S., et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14648-14653
41. Goodman K.J., et al. Dynamics of Helicobacter pylori infection in a US-Mexico cohort during the first two years of life. Int. J. Epidemiol. 34 (2005) 1348-1355
42. Colina R., et al. Translational control of the innate immune response through IRF-7. Nature 452 (2008) 323-328
43. Stojdl D.F., et al. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J. Virol. 74 (2000) 9580-9585
44. Schoenheimer R., and Rittenberg D. The application of isotopes to the study of intermediary metabolism. Science 87 (1938) 221-226
45. n and the chemiluminescent nitrogen detector. Anal. Chem. 74 (2002) 3232-3236
46. Liang Q., et al. Monitoring adenoviral DNA delivery, using a mutant herpes simplex virus type 1 thymidine kinase gene as a PET reporter gene. Gene Ther. 9 (2002) 1659-1666
47. 13C-labeled bicarbonate. Nature 453 (2008) 940-943
48. Leichert L.I., et al. Quantifying changes in the thiol redox proteome upon oxidative stress in vivo. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 8197-8202
49. Butterfield D.A., et al. Redox proteomics in some age-related neurodegenerative disorders or models thereof. NeuroRx 3 (2006) 344-357
50. Zhang J., and Goodlett D.R. Proteomic approach to studying Parkinson's disease. Mol. Neurobiol. 29 (2004) 271-288
51. Hansel B., et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab. 89 (2004) 4963-4971
52. Van Guilder G.P., et al. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity (Silver Spring) 14 (2006) 2127-2131
53. Phelps M.E. Positron emission tomography provides molecular imaging of biological processes. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9226-9233
54. Weber W.A., et al. Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat. Clin. Pract. Oncol. 5 (2008) 44-54
55. Mishani E., et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J. Med. Chem. 48 (2005) 5337-5348
56. 11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg. Med. Chem. Lett. 16 (2006) 4102-4106
57. 18F-fluoroazomycin arabinoside. J. Nucl. Med. 46 (2005) 106-113
58. 18F-Galacto-RGD PET. J. Nucl. Med. 49 (2008) 255-259
59. Backer M.V., et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat. Med. 13 (2007) 504-509
60. 99mTc-Annexin-V functional imaging of luminal thrombus activity in abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2153-2159
61. 18F-FDG. J. Nucl. Med. 44 (2003) 1426-1431
62. Judenhofer M.S., et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med. 14 (2008) 459-465
63. Weissleder R., and Pittet M.J. Imaging in the era of molecular oncology. Nature 452 (2008) 580-589
64. Jaffer F.A., et al. Molecular imaging of cardiovascular disease. Circulation 116 (2007) 1052-1061
65. Kirik D., et al. Imaging in cell-based therapy for neurodegenerative diseases. Eur. J. Nucl. Med. Mol. Imaging 32 Suppl 2 (2005) S417-S434
66. Radu C.G., et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [(18)F]-labeled 2′-deoxycytidine analog. Nat. Med. 14 (2008) 783-788
67. 13C magnetic resonance imaging and spectroscopy. Nat. Med. 13 (2007) 1382-1387
68. Davenport A.P., and Kuc R.E. Radioligand-binding and molecular-imaging techniques for the quantitative analysis of established and emerging orphan receptor systems. Methods Mol. Biol. 306 (2005) 93-120
69. Harris D.M., et al. GPCR signalling in hypertension: role of GRKs. Clin. Sci. 115 (2008) 79-89
70. Sakurai T., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 (1998) 573-585
71. Blagoev B., et al. Proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat. Biotechnol. 21 (2003) 315-318
72. Ray P., et al. Noninvasive quantitative imaging of protein-protein interactions in living subjects. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3105-3110
73. Doubrovin M., et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9300-9305
74. 2 receptor as a reporter gene in living animals. Gene Ther. 6 (1999) 785-791
75. 188Re. J. Nucl. Med. 41 (2000) 887-895
76. Haberkorn U., et al. Functional genomics and proteomics - the role of nuclear medicine. Eur. J. Nucl. Med. Mol. Imaging 29 (2002) 115-132
77. Barton K.N., et al. GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol. Ther. 8 (2003) 508-518
78. Peñuelas I., et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 128 (2005) 1787-1795
79. Riley T., et al. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9 (2008) 402-412
80. Yu Y., et al. Quantification of target gene expression by imaging reporter gene expression in living animals. Nat. Med. 6 (2000) 933-937
81. Burton J.B., et al. Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat. Med. 14 (2008) 882-888
82. Bayele H.K., and Srai S.K. Regulatory variation in hepcidin expression as a heritable quantitative trait. Biochem. Biophys. Res. Commun. 384 (2009) 22-27
83. Milenic D.E., et al. Antibody-targeted radiation cancer therapy. Nat. Rev. Drug Discov. 3 (2004) 488-499
84. Reichert J.M., and Valge-Archer V.E. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 6 (2007) 349-356
85. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147-1157
86. Wu A.M., and Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23 (2005) 1137-1146
87. von Mehren M., et al. Monoclonal antibody therapy of cancer. Annu. Rev. Med. 54 (2003) 343-369
88. Li L., et al. A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies. Bioconjug. Chem. 19 (2008) 89-96
89. Dadachova E., and Casadevall A. Radioimmunotherapy of infectious diseases. Semin. Nucl. Med. 39 (2009) 146-153
90. Gould P. Medical isotope shortage reaches crisis level. Nature 460 (2009) 312-313
91. McDevitt M.R., et al. Tumor therapy with targeted atomic nanogenerators. Science 294 (2001) 1537-1540
92. Gao X., et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22 (2004) 969-976
93. Campisi J. The biology of replicative senescence. Eur. J. Cancer 33 (1997) 703-709
94. Peltonen L., and McKusick V.A. Dissecting human disease in the postgenomic era. Science 291 (2001) 1224-1229
95. 18F]FMAU and positron emission tomography in patients with cancer. Eur. J. Nucl. Med. Mol. Imaging 32 (2005) 15-22